NNovo Nordisk Read More Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?2026-02-08 Eli Lilly’s (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes…